General methods
All reagents and solvents were purchased from commercial sources ABCR, Acros, Sigma-Aldrich, Fluka, VWR, Aplichem or Merck and used as such unless stated otherwise. Chromatographic purification was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å. TLC was performed on Merck silica gel 60 F254 TLC glass plates and visualized with UV light, permanganate stain or phosphomolybdic acid stain. Melting points were measured on a calibrated Büchi B-540 melting point apparatus using open glass capillaries. 1 H NMR spectra were recorded on a Bruker DPX-400 400 MHz spectrometer in CDCl 3 , CD 2 Cl 2 or DMSO-d 6 ; all signals are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal CD 2 Cl 2 signal at 5.32 ppm or the internal DMSO signal at 2.50 ppm as standard. The data is being reported as (s = singlet d = doublet t = triplet q = quadruplet quint = quintet m = multiplet or unresolved bs = broad signal, coupling constant(s) in Hz, integration, interpretation). 19 F NMR spectra were recorded on a Bruker DPX-400 376 MHz spectrometer in CDCl 3 . 13 C NMR spectra were recorded with 1 H-decoupling on a Bruker DPX-400 101 MHz spectrometer in CDCl 3 , CD 2 Cl 2 or DMSO-d 6 ; all signals are reported in ppm with the internal chloroform signal at 77.2 ppm, the internal CD 2 Cl 2 signal at 53.8 ppm or the internal DMSO signal at 39.5 ppm as standard. Infrared spectra were recorded on a JASCO FT-IR B4100 with an ATR device and a ZnSe prisma and are reported as cm −1 (w = weak, m = medium, s = strong, br = broad). High-resolution mass spectrometric measurements were performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API.
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Syntheses of starting materials
1. General procedure A for the synthesis of pyridinones
Following a reported procedure, 1 copper iodide (5 mol %), potassium phosphate tribasic (2.00 equiv), the corresponding 2-hydroxypyridine (1.00 equiv) and the corresponding 2-bromopyridine (2.00 equiv) were suspended in toluene [0. 4 M] under N 2 . N,N'-Dimethylethylenediamine (0.10 equiv) was added and the resulting mixture was stirred 20 h at 120 °C. The resulting mixture was allowed to cool to rt and then quenched with water. A small amount of N,N'-dimethylethylenediamine was added to dissolve the residual copper salts into the aqueous phase. The layers were separated and the aqueous layer was extracted three times with EtOAc (20 mL). The organic layers were combined, dried over MgSO 4 and concentrated under reduced pressure. A purification by flash chromatography (eluent DCM/EtOAc 1:1 with 4%vv of NEt 3 ) affordeded the desired product.
2H-[1,2'-Bipyridin]-2-one (5a)
Following general procedure A and starting from commercially available 2-hydroxypyridine (1.43 g, 15.0 mmol) and 2-bromopyridine (2.86 mL, 30.0 mmol), 5a (2.46 g, 14.3 mmol, 95%) (CAS number 3480-65-7) was obtained as a pale yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ 8.56 (d, J = 4.7 Hz, 1H, H Ar ), 7.94 (d, J = 8.2 Hz, 1H, H Ar ), 7.85 (ddd, J = 13.9, 7.4, 4.0 Hz, 2H, H Ar ), 7.38 (ddd, J = 8.9, 6.5, 2.0 Hz, 1H, H Ar ), 7.33-7.29 (m, 1H, H Ar ), 6 .64 (d, J = 9.2 Hz, 1H, H Ar ), 6 .29 (t, J = 6.8 Hz, 1H, H Ar ). 13 
5'-Methoxy-2H-[1,2'-bipyridin]-2-one (5b)
Following general procedure A and starting from commercially available 2-hydroxypyridine (143 mg, 1.50 mmol) and 2-bromo-5-methoxypyridine (564 mg, 3.00 mmol), 5b (231 mg, 1.14 mmol, 76%) (CAS number 10201-69-1) was obtained as a white solid.
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5'-(Trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (5c)
Following general procedure A and starting from commercially available 2-hydroxypyridine (143 mg, 1.50 mmol) and 2-bromo-5-(trifluoromethyl)pyridine (678 mg, 3.00 mmol), 5c (245 mg, 1.02 mmol, 68%) (CAS number 1845694-34-9) was obtained as a white solid. 
1-(Quinolin-2-yl)pyridin-2(1H)-one (5f)
Following general procedure A and starting from commercially available 2-hydroxypyridine (152 mg, 1.60 mmol) and 2-bromoquinoline (666 mg, 3.20 mmol), 5f (342 mg, 1.54 mmol, 96%) (CAS number 10168-48-6) was obtained as a white solid. 
3-Fluoro-2H-[1,2'-bipyridin]-2-one (5i)
Following general procedure A and starting from commercially available 3-fluro-2-hydroxypyridine (226 mg, 2.00 mmol) and 2-bromopyridine (0.38 mL, 4.0 mmol), 5i (281 mg, 1.48 mmol, 74%) (CAS number 1872255-08-7) was obtained as a white solid. 
4-(Trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (5k)
Following general procedure A and starting from commercially available 2-hydroxy- 
4-(Benzyloxy)-2H-[1,2'-bipyridin]-2-one (5l)
Following general procedure A and starting from commercially available 4-benzyloxy-2-hydroxypyridine (302 g, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 5l (113 mg, 0.410 mmol, 27%) (CAS number 1644063-36-4) was obtained as a white solid. 
5-Methyl-2H-[1,2'-bipyridin]-2-one (5m)
Following general procedure A and starting from commercially available 2-hydroxy-4-methylpyridine (458 mg, 4.20 mmol) and 2-bromopyridine (0.80 mL, 8.4 mmol), 5m (691 mg, 3.71 mmol, 88%) (CAS number 53427-88-6) was obtained as a white solid. 
2-(Pyridin-2-yl)isoquinolin-1(2H)-one (5n)
Following general procedure A and starting from commercially available isoquinolin-1(2H)-one (218 mg, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 5n (276 mg, 
4H-[1,2'-bipyridin]-4-one (5o)
Following general procedure A and starting from commercially available 4-hydroxypyridine (143 mg, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 5o (181 mg, 1.05 mmol, 70%) (CAS number 76520-27-9) was obtained as a yellow solid. Acetoxy-1,2-benziodoxol-3-(1H)-one (18) Following a reported procedure 7 , sodium periodate (18.1 g, 85.0 mmol, 1.05 equiv) and 2-iodobenzoic acid (20.0 g, 81.0 mmol, 1.00 equiv) were suspended in 30% (v:v) aq. AcOH (160 mL). The mixture was vigorously stirred and refluxed for 4 h and allowed to cool to room temperature, while protecting it from light. After 1 h, the crude product was collected by filtration. The crystals were washed with ice water (3 × 40 mL) followed by acetone (45 mL) and dried under reduced pressure in the dark to afforded 1-hydroxy-1,2-benziodoxol-3-(1H)-one (20.8 g, 79.0 mmol, 98%) as a white solid. Following a reported procedure, 1-hydroxy-1,2-benziodoxol-3-(1H)-one (20.8 g, 79.0 mmol, 1.00 equiv) was suspended in acetic anhydride (75.0 mL, 788 mmol, 10.0 equiv) and heated to reflux (140 °C) until complete dissolution (about 15 min). The resulting clears solution was slowly let to cool to room temperature and then cooled to 5 °C in the fridge. The white crystals were filtered, washed with pentane (3 × 30 mL) and dried under reduced pressure to afforded 1-acetoxy-1,2-benziodoxol-3-(1H)-one (22.3 g, 73.0 mmol, 92%) as a white solid.
Following a slightly modified reported procedure, 8 1-acetoxy-1,2-benziodoxol-3-(1H)-one (1.20 equiv), the corresponding azaheterocycle (1.00 equiv) and zinc(II) trifluoromethanesulfonate (0.20 equiv) were dissolved in DCM [0.05 M]. The reaction was stirred overnight at room temperature, directly purified by flash chromatography (eluent DCM/MeOH see ratio thereafter) and triturated in ACN to afforded the pure desired hypervalent iodine reagent.
1-(1-Methyl-1H-indol-3-yl)-1H-1λ 3 -benzo[b]iodo-3(2H)-one (6a)
Following general procedure C, starting from commercially available 1-methylindole (0.43 mL, 3.4 mmol) and 16, a purification by column chromatography (DCM/MeOH 19:1) affordeded the title compound 6a (0.79 g, 2.1 mmol, 61% yield) (CAS number 2130906-04-4) as an off-white solid. CDCl 3 ) δ 167.0, 138.7, 137.7, 133.6, 133.4, 132.7, 130.7, 129.5, 125.4, 124.5,  122.8, 120.1, 116.3, 110.9, 79.2, 34.1 . Spectra data matched with the values reported in literature. 
1-(5-Bromo-1-methyl-1H-indol-3-yl)-1H-1λ 3 -benzo[b]iodo-3(2H)-one (6b)
Following general procedure C, starting from 15b (406 mg, 
1-(1H-Indol-3-yl)-1H-1λ3 -benzo[b]iodo-3(2H)-one (6c)
Following general procedure C but replacing Zn(OTf) 2 
1-(6-Bromo-1H-indol-3-yl)-1H-1λ3 -benzo[b]iodo-3(2H)-one (6d)
Following general procedure C, but replacing Zn(OTf) 2 by Sc(OTf) 3 
General procedure D for the synthesis of 6-(indol-3-yl)-1,2'-bipyridin-2-ones
In a sealed tube, [RhCp*Cl 2 ] 2 (3.7 mg, 6.0 µmol, 3 mol %), AgSbF 6 (10.3 mg, 30.0 µmol, 0.15 equiv), Zn(OTf) 2 (10.9 mg, 30.0 µmol, 0.15 equiv), the corresponding pyridinone (0.20 mmol, 1.00 equiv) and the corresponding hypervalent iodine reagent (0.20 mmol, 1.00 equiv) were solubilized in dry MeOH (2.0 mL, 0.1 M) under N 2 . The mixture was stirred at 80 °C for 12 h. The suspension was diluted with DCM (5 mL) and quenched with a saturated aqueous solution of NaHCO 3 (5 mL). The two layers were separated and the aqueous layer was extracted twice with DCM (5 mL). The organic layers were combined, dried over magnesium sulfate dehydrate, filtered and concentrated under reduced pressure. The crude residue was purified by preparative TLC using DCM/MeOH 19:1 as eluent to afforded the pure title compound.
6-(1-Methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7a)
Following General Procedure D, starting from 5a and 6a, a purification by preparative TLC (DCM/ 
5'-Methoxy-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7b)
Following General Procedure D, starting from 5b and 6a, a purification by preparative TLC (DCM/ 
6-(1-Methyl-1H-indol-3-yl)-5'-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (7c)
Following General Procedure D, starting from 5c and 6a, a purification by preparative TLC (DCM/ 
6-(1-Methyl-1H-indol-3-yl)-1-(quinolin-2-yl)pyridin-2(1H)-one (7f)
Following General Procedure D, starting from 5f and 6a, a purification by preparative TLC (DCM/ Methyl-1H-indol-3-yl)-3-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (7h) Following General Procedure D, starting from 5h and 6a, a purification by preparative TLC (DCM/ 
3-Methyl-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7g)
Following
6-(1-
4-Methyl-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7j)
Following General Procedure D, starting from 5j and 6a, a purification by preparative TLC (DCM/ 
6-(1-Methyl-1H-indol-3-yl)-4-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (7k)
Following General Procedure D, starting from 5k and 6a, a purification by preparative TLC (DCM/ 
3-(1-Methyl-1H-indol-3-yl)-2-(pyridin-2-yl)isoquinolin-1(2H)-one (7n)
Following General Procedure D, starting from 5n and 6a, a purification by preparative TLC (DCM/ 
2-(1-Methyl-1H-indol-3-yl)-4H-[1,2'-bipyridin]-4-one (7o)
Following General Procedure D, starting from 5o and 6a, a purification by preparative TLC (DCM/ 
6-(6-Bromo-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7s)
Following General Procedure D, starting from 5a and 6d, a purification by preparative TLC (DCM/ 
